Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 50.6%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 25,900 shares, a growth of 50.6% from the July 31st total of 17,200 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is currently 0.0 days. Approximately 4.1% of the shares of the company are sold short.

Alzamend Neuro Stock Performance

NASDAQ:ALZN traded down $0.07 during trading hours on Thursday, reaching $2.30. The stock had a trading volume of 185,893 shares, compared to its average volume of 588,215. The company has a 50 day moving average price of $3.50 and a two-hundred day moving average price of $6.32. The stock has a market capitalization of $18.36 million, a PE ratio of -2.34 and a beta of 0.03. Alzamend Neuro has a 52 week low of $1.84 and a 52 week high of $44.79.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC purchased a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.38% of Alzamend Neuro at the end of the most recent reporting period. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.